Clinical Trials Sponsored by CSL Limited

Total 3526 results

CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
CSL Limited

Completed

Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

Healthy

Australia
CSL Limited

Completed

Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL

Acute Coronary Syndromes

Canada
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
CSL Limited

Completed

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Stable Atherothrombotic Disease

United States
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
CSL Limited

Completed

A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

Healthy

Australia
CSL Limited

Completed

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Australia
CSL Limited
Parexel

Completed

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Leukemia, Myeloid, Acute

United States, Australia
Hamilton Health Sciences Corporation
CSL Limited

Completed

Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma

Asthma

Canada
CSL Behring
CSL Plasma

Completed

Rabies Immune Plasma Booster Study

Rabies

United States
CSL Behring

Not yet recruiting

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

Hemophilia B
CSL Behring

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (IX-TEND 4001)

Hemophilia B

United States
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
CSL Behring

Recruiting

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Traumatic Injury

United States, United Kingdom, Australia
CSL Behring

Completed

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy

Poland, France, Germany, Belgium, Finland
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
CSL Behring

Active, not recruiting

Register of Patients With haEmophilia A tReated With Afstyla® (OPERA)

Haemophilia A

France
CSL Behring

Completed

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Canada, United Kingdom, Australia, Germany, Poland, Belgium, Austria, Denmark, Italy, Spain
CSL Behring

Completed

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Australia, Germany, Poland, Italy, United Kingdom
CSL Behring

Completed

Dose Confirmation Trial of AAV5-hFIXco-Padua

Hemophilia B

United States
CSL Behring

Completed

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Sickle Cell Disease

United States, United Kingdom, Netherlands
CSL Behring

Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Hidradenitis Suppurativa | Palmoplantar Pustulosis

Denmark, Australia, Germany
CSL Behring

Completed

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Healthy Participants

United States
CSL Behring

Terminated

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Coronavirus Disease 2019 (COVID-19)

Australia
CSL Behring

Terminated

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Anemia, Sickle Cell

United States
CSL Behring

Completed

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Italy, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
CSL Behring

Terminated

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Oral Mucositis

United States, Canada, Australia, Germany, Italy, Austria
CSL Behring

Terminated

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) (ALD518-010)

Acute GvHD

United States
CSL Behring

Completed

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
CSL Behring

Withdrawn

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Belgium, United States, Italy, Spain, France, Germany, United Kingdom, Argentina, Australia, Canada, Mexico, Poland, Switzerland
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)

Arthritis, Rheumatoid

Russian Federation, Serbia, Georgia, Canada, India, Poland
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
CSL Behring

Completed

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Congenital Fibrinogen Deficiency

United States, Canada
CSL Behring

Completed

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

Coagulation Protein Disorders | Perioperative Care | Blood Loss, Surgical

United Kingdom
CSL Behring

Completed

Extension Study of Biostate in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Germany, Poland, Russian Federation, Ukraine
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
CSL Behring

Completed

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Healthy

Germany
CSL Behring

Completed

Human Fibrinogen - Pharmacokinetics

Fibrinogen Deficiency

United States, Italy
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
CSL Behring

Completed

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Hereditary Angioedema

United States, Canada
CSL Behring

Completed

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure (BE1116_3003)

Reversal of Coagulopathy

United States, Belarus, Bulgaria, Lebanon, Romania, Russian Federation
CSL Behring

Completed

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Bulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery (REPLACE)

Surgical Blood Loss | Postoperative Blood Loss

United Kingdom, Canada, Japan, Italy, Poland, Germany, Czech Republic, Austria, Brazil, Denmark, Finland
CSL Behring

Completed

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Primary Immune Deficiency

United States
CSL Behring

Completed

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Common Variable Immunodeficiency | Agammaglobulinemia

Canada, Germany, Italy, Spain
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
CSL Behring

Completed

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Common Variable Immunodeficiency | Agammaglobulinemia | IgG Deficiency

United States

3

Subscribe